Can-Fite Secures Australian Patent for Namodenoson in Liver and Pancreatic Cancer
Event summary
- Can-Fite BioPharma received Australian patent allowance for Namodenoson in liver and pancreatic cancer treatments.
- Namodenoson is in a pivotal Phase 3 study for advanced hepatocellular carcinoma with FDA and EMA protocol agreement.
- The company completed a Phase 2a clinical study in pancreatic cancer, showing encouraging survival outcomes.
- Namodenoson targets the A3 adenosine receptor (A3AR), highly expressed in inflammatory and cancer cells.
The big picture
Can-Fite's Australian patent strengthens its global IP portfolio for Namodenoson, a drug targeting advanced oncological conditions. The strategic move aligns with broader trends in biotech where intellectual property protection is critical for market differentiation and revenue potential. With ongoing Phase 3 trials and plans for further studies, Can-Fite is positioning itself as a key player in the oncology space.
What we're watching
- Regulatory Progress
- How the FDA and EMA protocol agreement will impact the timeline for Namodenoson's approval in liver cancer.
- Clinical Trial Execution
- Whether Can-Fite can successfully transition from Phase 2a to Phase 2b in pancreatic cancer with gemcitabine combination therapy.
- Market Expansion
- The pace at which Can-Fite can leverage the Australian patent to expand Namodenoson's market reach beyond liver and pancreatic cancer.
Related topics